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ABSTRACT 
Carriage of interruptions in CTG repeats of the myotonic dystrophy protein kinase 
gene has been associated with a broad spectrum of myotonic dystrophy type 1 
(DM1) phenotypes, mostly mild. However, the data available on interrupted DM1 
patients and their phenotype are scarce. We studied 49 Spanish DM1 patients, 
whose clinical phenotype was evaluated in depth. Blood DNA was obtained and 
analyzed through triplet-primed polymerase chain reaction (PCR), long PCR-
Southern blot, small pool PCR, AciI digestion, and sequencing. Five patients of our 
registry (10%), belonging to the same family, carried CCG interruptions at the 3’ 
end of the CTG expansion. Some of them presented atypical traits such as a very 
late onset of symptoms (>50 years) and a severe axial and proximal weakness 
requiring walking assistance. They also showed classic DM1 symptoms including 
cardiac and respiratory dysfunction, which were severe in some of them. Sizes and 
interrupted allele patterns were determined, and we found a contraction and an 
expansion in two intergenerational transmissions. Our study contributes to the 
observation that DM1 patients carrying interruptions present with atypical clinical 
features that can make DM1 diagnosis difficult, with a later than expected age of 
onset and a previously unreported aging-related severe disease manifestation. 
 
THIS ARTICLE IS PROTECTED BY COPYRIGHT. ALL RIGHTS RESERVED. 
 
A
cc
ep
te
d 
A
rt
ic
le
 
INTRODUCTION 
Myotonic dystrophy type 1 (DM1, Steinert disease; MIM# 160900) is a 
multisystemic disorder with an overall estimated prevalence of 1:8000 (Harper PS, 
2001), being the most common form of inherited muscular dystrophy in adults. 
DM1 patients show wide phenotypic heterogeneity, not only in age of onset but 
also in severity and type of clinical manifestation. DM1 patients can be broadly 
divided into five subtypes based mainly on their age of onset: congenital (< 1 
month), childhood (1 month–10 years), juvenile (10–20 years), adulthood/classic 
(20–40 years), or late-onset (>40 years) (De Antonio et al., 2016). Classic DM1 
symptoms include muscle weakness, myotonia, respiratory failure, cardiac 
conduction defects, cataracts, and endocrine disturbances. The younger subtypes, 
congenital and childhood onset, are characterized primarily by cognitive and 
learning abnormalities (Douniol et al., 2012; Meola & Cardani, 2015).  
DM1 is an autosomal dominant disorder caused by a CTG expansion in the 3’ 
untranslated region of the myotonic dystrophy protein kinase (DMPK) gene. 
Unaffected individuals carry 5–35 CTG repeats whereas individuals carrying 
between 35 to 50 repeats are usually asymptomatic. Yet in the latter, DMPK alleles 
have a higher mutation rate and are labelled as ‘pre-mutational alleles’ (Imbert, 
Kretz, Johnson, & Mandel, 1993). The length of the CTG expansion varies widely 
between patients, ranging from 50 to thousands of CTGs and has been associated 
with age of symptom onset and severity (Groh et al., 2011; Logigian et al., 2004). 
A CTG repeat size ≤150 CTGs, ≤1000 CTGs and ˃ 1000 CTGs is common to late 
onset, adulthood/classic and congenital DM1, respectively (Meola & Cardani, 
2015). However, a high individual variability exists among DM1 patients of the 
same subtype and thus caution is needed when using CTG expansion length to 
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predict disease progression. For instance, congenital cases have been found with 
CTG repeat lengths clearly below 1000 CTG repeats (Tsilfidis, MacKenzie, 
Mettler, Barceló, & Korneluk, 1992) and late onset DM1 cases have been reported 
with over 1000 CTG repeats (Clark, Petty, & Strong, 1998). Another feature of the 
disease that makes it difficult to infer potential genotype/phenotype correlations is 
the presence of ‘somatic mosaicism’. Indeed, the CTG expansion is highly unstable 
in both germline and somatic cells, and this instability persists through the lifetime 
of the patient. Thus, the CTG repeat size of a given patient represents the mean 
value for different CTG repeat sizes, which in turn can vary depending on the age 
at which the patient is studied. These potential confounders for sizing CTG repeat 
makes it difficult to find genotype-phenotype correlations for DM1. In this respect, 
estimating the inherited allele length has proven to be a more accurate predictor of 
potential genotype-phenotype correlations in this disease. (Higham, Morales, 
Cobbold, Haydon, & Monckton, 2012; Morales et al., 2012).  
Because the aforementioned fact that CTG expansion instability is also present in 
germline cells, new alleles with different CTG repeat sizes are constantly generated 
and children may inherit CTG repeat sizes considerably longer than those found in 
the transmitting parent. This leads to the so-called ‘anticipation’ phenomenon, 
which occurs in DM1 and in other triplet disorders, and is characterized by the fact 
that the disease may develop earlier in life in each successive generation (Harper, 
Harley, Reardon, & Shaw, 1992). In DM1, the sex of the transmitting parent plays 
an important role in anticipation, although both paternal and maternal transmission 
have been described. The paternal allele seems more unstable and leads more 
frequently to higher expansions in offspring, especially with CTG expansions 
below 100 repeats (Brunner, Ashizawa 1992). However, very large expansions 
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causing congenital DM1 are transmitted almost exclusively by affected mothers 
(Ashizawa 1994), with few exceptions reported (Di Costanzo et al., 2009; 
Zeesman, Carson, & Whelan, 2002). On the other hand, the congenital form is 
frequently observed after transmission from mothers who are carriers of more than 
500 CTG repeats. Contractions of the CTG expansion upon transmission have also 
been reported, with a higher estimated prevalence in paternal transmission 
compared to maternal transmissions (6.7 vs. 19.5 %) (López de Munain et al., 
1996).  
In most cases, the CTG expansion in expanded DMPK alleles is an uninterrupted 
sequence. However, in the last decade, pathological variant expansions containing 
unstable CCG, CTC, GGC and CAG sequence interruptions at the 3´ and 5’ ends of 
the DMPK allele have been reported, with a prevalence of 3–5% among DM1 
(Botta et al., 2017; Braida et al., 2010; Cumming et al., 2018; Musova et al., 2009; 
Pešović et al., 2017; Santoro et al., 2013; Tomé et al., 2018). In addition, 
intergenerational transmissions typically lead to smaller CTG expansions when 
compared to non-interrupted DM1 families, suggesting a stabilizing effect of the 
expansion on germline transmission (Botta et al., 2017; Pešović et al., 2017; Tomé 
et al., 2018). These findings might also explain why no congenital cases have been 
described in maternal transmission of interrupted alleles. 
Most of the phenotype consequences of interruptions remain poorly understood and 
vary considerably between studies, ranging from a complex neurological 
phenotype to a later age of onset (Annalisa Botta et al., 2017; Braida et al., 2010; 
Cumming et al., 2018; Musova et al., 2009; Pešović et al., 2017; Massimo Santoro 
et al., 2015). There is an urgent need to determine the phenotypes that associate 
with the subset of DM1 patients presenting with interruptions. This information is 
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required for patient management, genetic counselling and future clinical trials. In 
the literature, only a few families and some isolated cases have been described, and 
their reported clinical data are scarce. In the present study, we have analyzed a 
large cohort of Spanish DM1 patients belonging to several families. Our aim was to 
identify DM1 patients carrying variant repeats and to perform an in-depth analysis 
of their clinical phenotypes. This might help to gain insight into the modifying 
effect that these repeat interruptions could have in DM1 diagnosis, clinical 
manifestation and patient follow-up. 
SUBJECTS AND METHODS 
Editorial Policies and Ethical Considerations 
This study was approved by the ethics committee of the University Hospital 
Germans Trias i Pujol (ref. PI-15-129) and was performed in accordance with the 
Declaration of Helsinki for Human Research. Written informed consent was 
obtained from all the participants. 
Participants 
Forty-nine DM1 patients belonging to 36 different families who were evaluated in 
our center during the 2015–2018 period participated in this study. Clinical and 
genetic information was collected and stored in a secure registry. Their clinical 
phenotype was evaluated by the neurologists of our team. Muscle strength was 
assessed using the manual Medical Research Council (MRC) scale. The most 
recent ophthalmological, cardiological and respiratory examinations carried out by 
the corresponding specialists were reviewed, as well as blood analyses, 
electrocardiograms, echocardiograms, and functional respiratory and swallowing 
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tests. Functional status and disability were assessed using the Muscular Impairment 
Rating Scale (MIRS), the modified Rankin Scale (mRS), and the Rasch-Built 
Myotonic Dystrophy type 1 activity and participation scale (DM1-Activ). 
DNA extraction and bidirectional triplet primed PCR 
Total genomic DNA was extracted from peripheral blood samples, as previously 
described (Miller, Dykes, & Polesky, 1988). To assess the size and the presence of 
interruptions in the expanded allele, all DM1 blood DNA samples were analyzed 
by bidirectional triplet primed-PCR (TP-PCR). TP-PCR was performed with 
primers DM1for-FAM, DM1-CAG-rev, and P3 at the 5’-end of the CTG 
expansion, or DM1rev-FAM, DM1-CTG-for, and P3 at the 3’ end of the CTG 
expansion, as previously described by Radvansky et al. (Radvansky, Ficek, 
Minarik, Palffy, & Kadasi, 2011). Both TP-PCRs (5’ and 3’) were performed with 
100 ng of genomic DNA, 10x PCR Buffer containing 15 mM of MgCl2, 10 nM of 
dNTP mixture , 0.5 U of TaKaRa DNA polymerase (TaKaRa), 3% DMSO and 0.2 
µM of each primer. PCR amplification conditions were the same for both TP-
PCRs: initial denaturation at 94°C for 5 min, followed by 34 cycles at 94°C for 1 
minute, 65°C for 1 minute, and 72°C for 2 minutes and a final extension step at 
72°C for 7 minutes. Correct amplification was assessed on a 2% agarose gel. PCR 
products were separated on an ABI PRISM 3130 Genetic Analyzer and data were 
analyzed with PeakScanner Software v1.0 (Applied Biosystems/MDS Sciex; CA). 
AciI digestion and Southern blot 
We used a digestion with AciI and Southern blot-long PCR strategy to determine 
presence of interruptions of the CCG/CGG type. DNA (100 ng) was amplified 
using the primers MDY1D-F GCTCGAAGGGTCCTTGTAGCCG and DM1-rev 
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GTGCGTGGAGGATGGAAC. The conditions of the long PCR were as follows: 
initial denaturation at 94°C for 4 min, followed by 35 cycles of denaturation at 
94°C for 30 sec and annealing-extension at 65°C for 7 min. Final extension was 
performed 65°C for 10 min. Fifty microliters of long PCR products were divided in 
two parts, one digested with AciI and the other not digested. An aliquot (10 µl) of 
each sample was resolved in an agarose gel and the products were detected by 
Southern blot hybridization. A DIG-labeled LNA probe (5’-
gcAgCagcAgCagCagcAgca-3’, with lower and upper-case letters representing an 
unmodified and an LNA nucleotide, respectively) was used to detect the 
expansions through chemiluminescence.  
Sequencing 
To determine the pattern of the interruptions we first amplified the DNA using 
primers GC1_CC, GC1_CCG, P2-rev and P3, as described elsewhere (Pešović et 
al., 2017). Products were resolved in a 3% agarose gel and purified using QIAquick 
gel extraction kit (Werfen, Barcelona, Spain). Purified products were sequenced 
with BigDye™ Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems). 
Sequences were analyzed with Chromas version 2.6.2. The DMPK gene reference 
sequence used was NG_009784.1. 
Small pool PCR and AciI digestion 
To estimate the length of the expanded progenitor allele (ePAL), small-pool PCR 
(SP-PCR) was carried out using flanking primers DM-C and DM-DR as previously 
described (Gomes-Pereira, Bidichandani, & Monckton, 2004; Monckton, Wong, 
Ashizawa, & Caskey, 1995). PCR was performed using Custom PCR Master Mix 
(Thermo Fisher Scientific, MA, USA) supplemented with 69 mM 2-
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mercaptoethanol, and Taq polymerase (Sigma-Aldrich UK, Gillingham) at 1 unit 
per 10 µL. All reactions were supplemented with 5% DMSO and the annealing 
temperature was 63.5°C. DNA fragments were resolved by electrophoresis on a 1% 
agarose gel, and Southern blot hybridized as described (Gomes-Pereira et al., 2004; 
Monckton et al., 1995). Autoradiographic images were scanned and ePAL 
estimated from the lower boundary by comparison against the molecular weight 
ladder, using CLIQS 1D gel analysis software (TotalLab UK, Newcastle upon 
Tyne). To analyze again the presence of CCG or CGG variant repeats, an 
additional step was added to the SP-PCR protocol. PCR products were purified 
using the QIAquick (Qiagen, Venlo, the Netherlands) PCR purification kit and split 
into two aliquots, one of which was digested with AciI. They were then resolved 
and blotted as before. 
RESULTS 
Clinical phenotypes 
Five of 49 DM1 patients (~10%) were found to have interruptions in the 3’ end of 
the CTG expansion. They belonged to the same family (Figure 1). Patient P1, P2 
and P3 are sisters who paternally inherited the disease, and patient P4 is the son of 
P2 (Figure 1) whereas patient P5 is the daughter of P3. A summary of their clinical 
characteristics is shown in Table 1. 
Patient P1 is the oldest of the siblings, and currently the most severely affected of 
all five patients. The first symptom she reported was weakness at the age of 52. 
Subsequently, she developed a generalized weakness, which interfered with her 
ability to cope with daily life activities. We studied her when she was 72-year-old 
and the most striking feature upon clinical examination was severe axial weakness 
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with dropped-head. The patient also presented with mild weakness in the upper and 
lower limbs, with only little myotonia. Another remarkable fact was that she had 
moderate facial weakness, but almost no ptosis and no temporal atrophy. She also 
presented with bilateral cataracts, dysphagia for liquids and frontal baldness. She 
had a heart pacemaker implanted since the age of 71 and used nocturnal 
noninvasive mechanical ventilation, and had no cognitive impairment. 
Patient P2: Symptoms started at the age of 50 with mild fatigue and myotonia. At 
the moment of inclusion in the study (aged 62), the clinical examination revealed 
only mild weakness of the neck flexor muscles, with mild handgrip myotonia and 
minimum ptosis. Complementary explorations showed a first-degree 
atrioventricular block and low values of maximum inspiratory and expiratory 
pressure (38% and 22% of normal, respectively), and of both forced vital capacity 
(81%) and expiratory volume in 1 second (96%). The patient presented with 
bilateral cataracts and severe baldness. No limb weakness, dysphagia or cognitive 
impairment was found.  
Patient P3: The first sign reported was handgrip myotonia in her fifties. At the 
moment of examination (age 60) she also had severe axial weakness with mild 
proximal limb weakness and moderate distal weakness. Like her oldest sister 
(Patient P1), she had moderate facial weakness with no ptosis or temporal atrophy. 
She also presented with bilateral cataracts, frontal baldness and dysphagia for 
liquids. Cardiological studies revealed a first-degree atrioventricular block. No 
respiratory or cognitive involvement was found. 
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Patient P4: This male patient (aged 35 years) carrying an interrupted allele was 
asymptomatic upon clinical examination and had no detectable myotonia or cardiac 
alterations. 
Patient P5: She was diagnosed at age of 25 based on the family history, although 
clinical manifestation did not start until two years later, starting with handgrip 
myotonia. At the moment of assessment (age 32) she presented with mild neck 
flexor and facial weakness and handgrip and percussion myotonia, without limb 
weakness. She has a first-degree atrioventricular block and cataracts, but no 
respiratory impairment.  
Molecular analysis of interruptions 
Interrupted alleles were firstly detected as gaps in the pattern of contiguous peaks 
detectable by capillary electrophoresis by 3’ TP-PCR (Figure 2). Patients P2 and 
P4 showed a similar interruption pattern, while P1, P3 and P5 showed different 
interruption patterns (Figure 2). No alterations where found with 5’ TP-PCR 
(Supp. Figure S1) 
We performed an AciI digestion of PCR products to test for the presence of CCG 
or GGC variant repeats in patients P1–5. In all these patients, the results showed a 
downward shift of the smear in the gel of the digested product compared to the 
non-digested product (Figure 3). This indicated that AciI had cleaved the PCR 
product and the interruption was likely either a CCG or a GGC triplet. In addition, 
since the bidirectional TP-PCR performed in the entire cohort was limited to the 
outer regions of the CTG expansion, we performed an AciI digestion in the entire 
DM1 cohort to search for possible undetected CCG or GGC interruptions in the 
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middle region of the CTG expansion. No additional CCG or GGC interruptions 
were found in our 44 remaining DM1 patients. 
Sequencing revealed the presence of several CCG interruptions in the CTG 
expansion of our five patients carrying interrupted alleles (Figure 4). The pattern 
of CCG interruptions was identical in the mother (patient P2) and son (P4), but 
different between all the other family members (patients P1, P3 and P5). In P1, we 
found some isolated CCG repeats scattered across the expansion. Patients P2 and 
P4 showed a complex CCG pattern, with one pair of CCGs together with other 
isolated CCG repeats. Patient P3 had a few CCGCTG hexamers, but inside of a 
more complex pattern including CCG interruptions in other positions. Patient P5 
(the daughter of P3) showed a pattern similar to that of her mother with respect to 
the hexamers, but with some extra CCGs located in different positions, generating 
three consecutive CCG repeats. During the sequencing process, we purified 
different bands from the same patient to assess the influence of somatic instability 
in the interruption pattern (Figure 4B). In the different bands analyzed, the same 
pattern was observed in each patient.  
SP-PCR (Figure 5) provided information on the repeat size of the ePAL for some 
of the patients: P1, 319 CTGs; P2, 241 CTGs; P4, 222 CTGs; P5, 547 CTGs. The 
expansion range due to the instability of the repeat was also determined: P1, 319 to 
900 CTGs; P2, 241 to 651 CTGs; P4, 222 to 332 CTGs; and P5 = 547 to 897 
CTGs. For patient P3, the expanded allele did not amplify well under these 
conditions, so it was not possible to determine ePAL or expansion range. This may 
be due to the specific pattern of variant repeats present. However, in the SP-PCR 
we could amplify 368 CTGs, which was the only sizing of the expanded allele that 
we could make. Additionally, the type of interruptions were analyzed through AciI 
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digestion in SP-PCR experiments, which again showed that the interruptions were 
of the CCG type (data not shown). By comparing the range of these bands, we 
could determine a contraction in the repeat size from patient P2 to P4 (i.e., from 
mother to son) but an expansion from patient P3 to P5 (i.e., from mother to 
daughter). This expansion was also linked to anticipation, with an early age of 
onset for P5 when compared to her mother (P3). 
Discussion 
The effect of variant repeat patterns on DM1 clinical phenotype is still unclear. On 
one hand, this genetic alteration has been shown to be associated (albeit in one 
family only) with a complex co-segregated neurological phenotype, including an 
intermediate Charcot-Marie-Tooth neuropathy, early hearing loss and 
encephalopathic attacks (Braida et al., 2010). On the other hand, variant repeats 
have been associated with a milder or atypical phenotype, including a later age of 
onset (Cumming et al., 2018; Musova et al., 2009; Pešović et al., 2017), a DM2-
like muscle phenotype (Pešović et al., 2017), as well as with an absence of 
muscular dystrophy (Musova et al., 2009) or central nervous system symptoms 
(Santoro, Masciullo, Silvestri, Novelli, & Botta, 2017). These reports have led to a 
tendency to believe that patients with interrupted alleles have some atypical 
symptoms, but overall a milder phenotype than their age-matched DM1 non-
interrupted peers with a similar repeat length. In this respect, we had the unique 
possibility to study a family containing interrupted cases of whom three were aged 
above 60 years. In this regard, although our data were obtained in a small number 
of patients within the same family, our results support the occurrence of atypical 
DM1 features and late age of onset, but not of a milder phenotype in patients 
carrying interruptions.  
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Despite the fact that several of the classical symptoms of DM1 could be found in 
the three sisters — such as myotonia, cataracts and cardiopathy — some 
peculiarities need to be highlighted. An atypical trait was the distribution pattern of 
muscle weakness in two of the sisters. Indeed, besides the distal limb weakness 
commonly found in DM1 patients, these two sisters presented with proximal limb 
weakness and severe axial involvement. One of them also had a dropped-head, 
which resembled a limb-girdle muscle dystrophy and severely affected her ability 
to perform activities of daily living. Another atypical trait of these patients is that 
they did not have the typical myopathic face expected in DM1 patients, despite the 
presence of moderate facial weakness. Although the interrupted cases showed 
several classic DM1 symptoms, the presentation of atypical symptoms could 
interfere with (and thus delay) the diagnosis.  
Based on the algorithm published by Morales et al (Fernando Morales et al., 2012), 
the ePAL of patients P1, P2 and the expanded allele size of P3 should be 
theoretically associated with an age of onset around 30s whereas in our patients 
symptoms did not actually start until they were in their 50s. In this regard, it should 
be first noted that it is very difficult to assess the age of onset in DM1 patients. The 
definition of age of onset refers to the age at which an individual starts to develop 
one or more clinical features or symptoms of a disease. In actual clinical practice, 
this depends on the capacity of the patient to report such symptoms or to remember 
the time when they started, and also on the ability of the physician to recognize 
them. Thus, the reported age of onset can be quite variable, depending on which 
symptoms are searched for by the physician and on the patient’s own reports. Our 
patients P1–3 (the three sisters) reported their first symptoms in their 50s (being 
myotonia, and difficulty to walk, the first abnormalities that made them suspect 
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they had a major medical condition). Patient P4 was a 35-year-old and was still 
asymptomatic. Based on his ePAL length (222 CTGs), he should show a classic 
DM1 phenotype (Morales et al., 2012), but no signs could be detected upon 
neurological examination. This late onset of symptoms has been previously 
reported in interrupted DM1 families and seems to be a fingerprint for most of the 
cases (Botta et al., 2017; Cumming et al., 2018; Musova et al., 2009; Pešović et al., 
2017).  
In the family we studied, anticipation was observed in one of the two 
intergenerational transmissions that we assessed, since in the other 
intergenerational transmission one of the patients (P4) was still asymptomatic. In 
patient P5 (whose first symptom was myotonia, at the age of 27), we found a 
bigger size of the expansion and an earlier age of onset than her progenitor. 
Although this anticipation in interrupted families has been previously reported 
(Pešović et al., 2017), after reviewing all the published families (Table 2), we 
assessed anticipation in every single reported family. In the rest of 
intergenerational transmissions reported, and in the case of our patients P2 and P4, 
anticipation could not be assessed since patients in the next generation are still 
asymptomatic. The explanation for these findings is not apparent, since anticipation 
is not expected in these families; indeed, interruptions are thought to be related to a 
stabilization or even contraction of the pathological expansion (Braida et al., 2010; 
Cumming et al., 2018; Musova et al., 2009; Pešović et al., 2017; Tomé et al., 
2018). However, anticipation was found in our studied intergenerational 
transmission, with this finding being also reported in other interrupted DM1 
patients based on reported age of onset (Table 2). In our family, no congenital, 
childhood or juvenile cases of DM1 were observed. Among the interrupted families 
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reported in the literature (Table 2), at least three juvenile DM1 cases (age < 18 
years) have been described (Braida et al., 2010; Pešović et al., 2017), but no 
congenital or childhood case. Thus, absence of infantile DM1 seems also to be a 
distinctive trait for interrupted expansions. 
The prevalence of interrupted alleles among our patients was ~10%, and 3% among 
the studied DM1 families. This is in overall agreement with previous studies in 
which the prevalence in families ranged from 3 to 5% (Botta et al., 2017; Braida et 
al., 2010; Musova et al., 2009; Pešović et al., 2017). The type of interruption 
present in our cohort was CCG, which is currently the most frequently reported 
variant repeat. However, the difficulties we experienced in characterizing the 
pattern of interruptions in our family members must be emphasized, with such 
difficulties mainly due to a technical limitation of TP-PCR and sequencing, which 
have a limited ability to detect interruptions deeper inside the expansion. In 
addition, characterization is affected by the PCR slippage and by somatic 
mosaicism (implying more noise in readouts and thus a higher difficulty to identify 
the interrupted pattern). Our sequences showed in some cases double peaks of C 
and T at the same position, and we decided to consider only those interruptions 
where the C peaks were above T in the electropherograms, which might have 
resulted in loss of CCG interruptions in our patients’ sequences. We sequenced 
several amplified bands coming from the same TP-PCR to determine whether 
somatic mosaicism was also affecting the pattern of CCG interruptions, but the 
same patterns were found in all the sequences. Despite the aforementioned 
limitations, we determined the interrupted pattern in all the studied family 
members. We observed a substantial change in the interruption pattern in every 
transmission, and the number and position of the CCGs changed in every 
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generation, except one intergenerational transmission. Thus, interruption patterns 
can be conserved or vary upon transmission. Both situations have been previously 
described in interrupted families (Musova et al., 2009; Pešović et al., 2017; Tomé 
et al., 2018). Our CCG interruptions were found in blocks of two or three (in 
hexamers of CCGCTG that were repeated two or three times), and also as isolated 
cases. Due to technical limitations, we cannot be certain that other interruptions are 
not present deeper in the CTG expansion. TP-PCR and sequencing allowed us to 
study the flanking regions of the CTG expansion, but the middle part remained 
undetected. We detected contraction of the expansion between patients P2 and P4, 
but expansion between patients P3 and P5. Previous studies suggest that CTG 
expansion containing variant repeat patterns display more frequently stable, or even 
contracted, DMPK alleles instead of further expanded DMPK alleles (Cumming et 
al., 2018; Musova et al., 2009; Pešović et al., 2017; Tomé et al., 2018). However, 
some studies have also found expansion of the interrupted alleles from one 
generation to the other (Braida et al., 2010; Cumming et al., 2018; Pešović et al., 
2017). Perhaps these expansions are less frequent than in pure CTG expansions 
transmission, but they do occur. Therefore, caution is needed with genetic 
counseling with regard to prospective parents with DM1.  
Our study contributes to the observation that DM1 patients carrying interruptions 
may have atypical symptoms that can make the diagnosis of DM1 difficult, with a 
later age of onset and a previously unreported aging-related severe disease 
manifestation. Indeed, some of our older patients needed mechanical ventilation 
and a pacemaker, and besides their cardiorespiratory problems, they had muscle 
weakness with subsequent impairment in daily life activities and walking ability. 
Despite the small sample size of our study sample, our results challenge the notion 
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that interrupted patients who remain asymptomatic until their late 30s or 40s are 
not at risk for having a severe phenotype later in life. Indeed, our patients 
developed a classical DM1 phenotype after their 50s. These patients require 
clinical follow-up and genetic counselling similar to non-interrupted DM1 patients. 
In the family we studied, we found some characteristics that add to the current 
body of knowledge regarding interrupted families: a later age of onset, variation of 
CCG repeat pattern between intergenerational transmission, anticipation due to the 
earlier age of onset of symptoms in next generation and no cases of congenital or 
childhood onset of DM1. In addition, we have found other previously undescribed 
characteristics, such as a predominant axial weakness. However, the small number 
of interrupted patients present in the DM1 population makes it hard to perform 
genotype-phenotype correlations and there is still much uncertainty. Studies with 
larger DM1 cohorts, preferably with DM1 families, are needed to unravel the 
phenotypic consequences of variant repeat patterns and to study their effect on 
intergenerational transmissions of the DMPK expanded allele. 
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Figures 
Figure 1. Pedigree of the interrupted patients in our cohort. Patient P1 = P1; Patient 
P2 = P2; Patient P3 = P3; Patient P4 = P4; Patient P5 = P5. Years = yr; Number of 
repeats in CTGs = CTGs. The father of P1, P2 and P3 died (sudden cardiac death). 
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Figure 2. Peak scan results of TP-PCR of the 3’ end, obtained with DNA extracted 
from blood. Interruptions indicated by black box. P1 = Patient P1; P2= Patient P2; P3= 
Patient P3; P4 = Patient P4; P5 = Patient P5.  
 
 
 
Figure 3. Southern blot of long PCR products from patients carrying variant repeats. 
For each patient, we show two conditions: digestion with (+) and without (-) the enzyme 
AciI (recognizing the pattern CCGC). P1= Patient P1; P2 = Patient P2; P3 = Patient P3; 
P4 = Patient P4; P5 = Patient P5; M = molecular weight marker; WT = wild type; bp = 
base pairs. 
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Figure 4. Sequencing the interrupted alleles. A) Schematic structure of DMPK 
expanded alleles of the interrupted DM1 family in our study. CTG repeats are shown in 
white, CCG repeats in black. Indicated size ranges were estimated by Southern Blot 
analysis. B) Cutting and purifying strategy for several bands of PCR product (indicated 
by arrows), from each interrupted patient, which are affected by somatic instability. C) 
Sequences showing the CCG interruptions are marked by black rectangles. P1= Patient 
P1; P2 = Patient P2; P3 = Patient P3; P4 = Patient P4; P5 = Patient P5; M = molecular 
weight marker; Bl = PCR reaction with no DNA. The DMPK gene reference sequence 
used was NG_009784.1. 
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Figure 5 Small pool PCR from patients carrying variant repeats. For each patient 
several lines show the normal and the expanded alleles. P1= Patient P1; P2 = Patient P2; 
P3 = Patient P3; P4 = Patient P4; P5 = Patient P5; CTGs = number of repeats; WT allele 
= wild type allele. 
 
Table 1. Clinical characteristics of the interrupted cases 
 P1 P2 P3 P4 P5 
Sex Female Female Female Male Femal
e 
Age of onset 
(years) 
52 50 50 Asymptomati
c 
27 
Age of 72 62 60 35 32 
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assessment 
(years) 
Cardiopathy Pacemake
r 
1st 
degree 
AV-block 
1st degree AV-
block 
None 1st 
degree 
AV-
block 
Respiratory 
disturbance 
Yes, 
nocturnal 
NMV 
Alteratio
n MIP & 
MEP 
None None None 
Dysphagia Liquids No Liquids None None 
Cognitive 
impairment 
None None None None None 
Cataracts Yes Yes Yes None Yes 
Metabolic 
disturbance 
None None Hypothyroidis
m 
None None 
Myotonia  Yes Yes Yes None Yes 
Polyneuropath
y 
None None None None None 
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CK level Normal Normal 213 U/L  Normal ND 
Limb Weakness  
Facial ptosis Yes Mild Yes None Mild 
Flexor/extens
or neck 
1 
(Dropped 
head) 
4 2 5 5 
Axial weakness Severe None Severe None None 
Upper Limb 
proximal 
(MRC) 
4 5 4 5 5 
Upper Limb 
distal (MRC) 
4 5 3 5 5 
Lower Limb 
proximal 
(MRC) 
4 5 4 5 5 
Lower Limb 
distal (MRC) 
4 5 3 5 5 
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6 MWT 
(meters) 
250 436 240 658 800 
MIRS 4 2 4 1 2 
mRS 3 1 3 0 2 
DM1-Activ 23 37 23 40 39 
CK, creatine kinase; ND, not determined; MRC, Medical Research Council; 6 
MWT, six-minute walking test; MIRS, Muscular Impairment Rating Scale; mRS, 
modified Rankin Scale; DM1-Activ, Rasch-built myotonic dystrophy type 1 
activity and participation scale; AV, atrioventricular; NMV, non-invasive 
mechanical ventilation; MIP, maximum inspiratory pressure; MEP, maximum 
expiratory pressure. 
Table 2: Analysis of the literature reported interrupted families 
Arti
cle 
Cas
es 
Pat
ient 
Cod
e 
A
g
e 
S 
A
ge 
O 
Relati
onship 
Antici
pation  
Atypical 
findings 
in 
examinati
on 
CT
G 
Rep
eats 
Nu
mbe
r 
Type 
of 
Interr
uption 
Mus
ova 
et al 
2009 
3 
fam
ilies       
  
 
Fa
mil
y A 
A-1 
(Fet
us) 0  
Fetus 
of A2   
230 CTC & 
CCG 
  A-2 
3
1 - 
Daugh
ter of NPS  
300 CTC & 
CCG 
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A4 
  A-3 
2
3 - 
Daugh
ter of 
A4 NPS  
400-
500 
CTC & 
CCG 
  A-4 
5
4 
40
s 
Brothe
r of A5   
600-
800 
CTC & 
CCG 
  A-5 
5
3 
40
s 
Sister 
of A4  
Electromy
ography 
confirmed 
myotonia 
but no 
dystrophy 
450-
650 
CTC & 
CCG 
  A-6 
2
9 - 
Daugh
ter of 
A5 NPS  
600-
750 
CTC & 
CCG 
  A-7 
3
1 - 
Son of 
A5 NPS  
270 CTC & 
CCG 
 
Fa
mil
y B B-1 
5
0 
40
s 
Father 
of B2  
No muscle 
weakness 
or muscle 
atrophy 
450 CCG 
  B-2 
2
5 - 
Son of 
B2 NPS  
400 CCG 
 
Fa
mil
y E E-1 
2
0 
1 
ye
ar
* 
Son of 
E2  
Upper 
limbs 
showed no 
muscle 
atrophy, 
weakness 
or 
myotonic 
reaction 
43 CCG 
  E-2 
5
6 - 
Father 
of E1 A  
43 CCG 
Braid
a et 
al 
2010 
1 
fam
ily       
  
 
Fa
mil
y 1 
III-
9 
5
5 25 
Cousin 
of III-
17 and 
III-16  
Charcot-
Marie-
Tooth 
disease, 
229P CCG & 
GGC 
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acute 
encephalop
athy and 
early 
hearing 
loss 
  
III-
16 
5
7 44 
Sister 
of III-
17  
Charcot-
Marie-
Tooth 
disease, 
acute 
encephalop
athy and 
early 
hearing 
loss 
170P CCG & 
GGC 
  
IV-
19 
3
7 20 
Son of 
III-16 A 
Charcot-
Marie-
Tooth 
disease, 
acute 
encephalop
athy and 
early 
hearing 
loss 
213P CCG & 
GGC 
  
IV-
20 
3
4 24 
Son of 
III-16 A 
Charcot-
Marie-
Tooth 
disease 
213P CCG & 
GGC 
  
III-
17 
6
1 35 
Sister 
of III-
16  
Charcot-
Marie-
Tooth 
disease, 
acute 
encephalop
athy and 
early 
hearing 
loss 
179P CCG & 
GGC 
  
IV-
21 
3
0 
17
# 
Son of 
III-17 A 
Charcot-
Marie-
Tooth 
disease 
220P CCG & 
GGC 
  
IV-
22 
2
8 25 
Daugh
ter of 
III-17 A 
Charcot-
Marie-
Tooth 
225P CCG & 
GGC 
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A
cc
ep
te
d 
A
rt
ic
le
 
disease 
Botta 
et al 
2016 
3 
fam
ilies       
  
 
Fa
mil
y A A1 
6
6 58 
Father 
of A2  
Absence of 
myotonia 
and 
cataracts 
100
0-
140
0 
CCG 
  A2 
3
9 31 
Daugh
ter of 
A1 A 
Absence of 
muscle 
weakness 
475-
640 
CCG 
  A3 0 
N/
A 
Fetus 
of A2   
500 CCG 
 
Fa
mil
y B B1 
5
5 51 
Mothe
r of B2   
740-
930 
CCG 
  B2 
2
8 - 
Dauthe
r of B1 NPS  
450-
550 
CCG 
 
Fa
mil
y C C1 
5
8 58 
Mothe
r of C2  
Absence of 
muscle 
weakness 
and 
cataracts 
140 CCG 
  C2 
4
0 37 
Daugh
ter of 
C1 A 
Absence of 
muscle 
weakness 
and 
cataracts 
121 CCG 
  C3 0 
N/
A 
Fetus 
of C2   
113 CCG 
Peso
vic et 
al 
2017 
3 
fam
ilies       
  
 
Fa
mil
y 
DF
1 
DF
1-1 
5
7 39 
Mothe
r of 
DF1-2 
and 
DF1-3   
520-
125
0 
CCG 
  
DF
1-2 
3
7 30 
Son of 
DF1-1 A 
Absence 
of: 
370-
730 
CCG 
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A
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ep
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d 
A
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le
 
percussion 
myotonia, 
ptosis, 
cataracts 
and 
muscle 
wasting. 
Presence 
of calf 
hypertrop
hy, 
suggesting 
DM2  
  
DF
1-3 
3
0 
15
# 
Son of 
DF1-1 A 
Calf 
hypertrop
hy 
450-
970 
CCG 
 
Fa
mil
y 
DF
2 
DF
2-1 
4
5 40 
Father 
of 
DF2-2  
Similar 
involveme
nt of both 
proximal 
and distal 
muscles 
and 
winging 
scapulae in 
the right 
side. 
320-
600 
CCG 
  
DF
2-2 
1
4 
12
# 
Daugh
ter of 
DF-1 A 
Mild 
ptosis and 
mild 
percussion 
myotonia 
200-
240 
CCG 
 
Fa
mil
y 
DF
5 
DF
5-2 
2
7 22 
Sister 
of 
DF5-3  
Normal 
strength of 
the 
sternocleid
omastoid 
muscle 
and very 
mild 
myotonia 
250-
350 
CTC 
  
DF
5-3 
2
2 21 
Sister 
of 
DF5-2   
300-
620 
Non-
Interru
pted 
Cum
ming 
et al 
3 
fam
ilies       
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A
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d 
A
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2018 
 
Fa
mil
y 1 14 
2
5,
5 - 
Daugh
ter of 
165 NPS 
Absence of 
muscle 
weakness, 
myotonia 
and 
cataracts 
381e
PAL 
CCG 
  57 
2
0,
5 5 
Son of 
165 A  
597e
PAL 
Non-
Interru
pted 
  165 
5
9 28 
Brothe
r of 83   
383e
PAL 
Non-
Interru
pted 
  83 
4
6 38 
Brothe
r of 
165   
105e
PAL 
Non-
Interru
pted 
 
Fa
mil
y 2 182 
3
5,
5 - 
Brothe
r of 
184 NPS 
Absence of 
muscle 
weakness, 
mild 
masseter 
myotonia 
and 
peripheral 
membrane 
irritability 
on EMG.  
293e
PAL 
CCG 
  184 
2
8 20 
Brothe
r of 
182   
288e
PAL 
Non-
Interru
pted 
  206 
7
0 60 
Father 
of 182 
and 
184   
90eP
AL 
Non-
Interru
pted 
  242 
6
5 
N
D 
Sister 
of 206   
80eP
AL 
Non-
Interru
pted 
 
Fa
mil
y 3 15 
3
9 - 
Daugh
ter of 
234 NPS 
No clinical 
apparent 
weakness 
or 
myotonia 
and no 
cataracts 
303e
PAL 
CCG 
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A
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d 
A
rt
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   54 40 35 Brother of 15   
146e
PAL 
Non-
Interru
pted 
  234 
N
D 
N
D 
Father 
of 15 
and 54   
496e
PAL 
Non-
Interru
pted 
Our 
stud
y 
1 
fam
ily       
  
 
Fa
mil
y 1 
Pati
ent 
1 
7
2 52 
Sister 
of 
Patient 
2 and 3  
Severe 
axial 
weakness 
with 
dropped-
head. Mild 
weakness 
in upper 
and lower 
limb 
muscles, 
with only 
little 
myotonia. 
Moderate 
facial 
weakness, 
almost no 
ptosis and 
no 
temporal 
atrophy 
319e
PAL 
CCG 
  
Pati
ent 
2 
6
2 50 
Sister 
of 
Patient 
1 and 3  
Mild 
weakness 
of the neck 
flexor 
muscles, 
no limb 
weakness 
and 
minimum 
ptosis 
241e
PAL 
CCG 
  
Pati
ent 
3 
6
0 50 
Sister 
of 
Patient 
1 and 2  
Severe 
axial 
weakness, 
mild 
proximal 
limb 
368 CCG 
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weakness 
and 
moderate 
distal 
weakness. 
Moderate 
facial 
weakness 
with no 
ptosis or 
temporary 
atrophy 
  
Pati
ent 
4 
3
5 - 
Son of 
Patient 
3 NPS  
222e
PAL 
CCG 
  
Pati
ent 
5 
3
2 27 
Daugh
ter of 
Patient 
2 A 
Mild neck 
flexor and 
facial 
weakness, 
but no 
limb 
weakness. 
547e
PAL 
CCG 
Age S= age of Sampling; Age O= age at Onset; N/A= not applicable; - = 
asymptomatic; ND= no data; NPS = not possible to establish yet; A = 
anticipation; *authors clarify in the paper that he had isolated symptoms, 
cannot be considered childhood DM1. ePAL estimated progenitor allele. 
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